Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)

Research output

Research output per year 2018 2018 2018

• 2 Citations
• 1 Comment/debate

Research output per year

Research output per year

Search results

• 2018

  2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

  Landmesser, U. (Lead / Corresponding author), Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M. F., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L. & Pinto, F. & 3 others, Tokgozoglu, L., Bax, J. J. & Catapano, A. L., 7 Apr 2018, In: European Heart Journal. 39, 14, p. 1131-1143 13 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  File

  • Clinical Guidance 100%
  • Homozygous Familial Hypercholesterolemia (HoFH) 100%
  • Atherosclerotic Cardiovascular Disease (ASCVD) 100%
  • Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors 100%
  • Coronary Artery Atherosclerosis 100%
  181 Citations (Scopus)

  162 Downloads (Pure)